Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 2, 1999

View Archived Issues

Pharmacokinetic and efficacy studies reported for novel prostate cancer drug

NuOncology Labs awarded U.S. patent for anticancer compounds

Sepracor: Q2 1999 highlights

Anti-VEGF enhances efficacy of radiation therapy

A review of SSRI-induced female sexual dysfunction and treatment strategies

Structural Bioinformatics and BioChem Pharma enter second drug discovery collaboration

Positive results achieved in primate studies of Titan's Spheramine

Cyberonics receives expedited review status for depression therapy

Aviron and Medeva extend FluMist collaboration

Matritech seeks expanded use for bladder cancer diagnostic

Allergan's second quarter highlights characterized by new agreements

Vertex' neurophilin ligands show neuroprotective effect in models of Parkinson's disease

New apoptosis inducers claimed by Takara Shuzo

Novel selectin inhibitors revealed in the patent literature by Sumitomo

Taisho, Nihon Nohyaku continue research into MDR ligands

Novel antifungal agents, chymase inhibitors isolated by Shionogi

U.S. patent provides protection for Cyclacel's Penetratin drug delivery technology

ThromboSol to be studied in chemotherapy recipients at M.D. Anderson

Vitex, Pentose announce merger agreement

BP-897, a partial dopamine D3 receptor agonist with potential in treating cocaine dependency

Solimastat is a potent MMP inhibitor with significant advantages over related compounds

Brazilian trial of Biotech Holdings' diabetes drug completed

Mutual recognition granted to Agrippal; vaccine to be marketed throughout Europe

OSI grants nonexclusive license for gene transcription patents to Pharmacia & Upjohn

Pharmacia & Upjohn receives approvable letter from FDA for Vestra

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 12, 2025.
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026